ITINERARE integrates three major axes on gene therapy, molecular therapies, and ethics, legal and social innovations (ELSI). Our team consists of 14 principal investigators from 5 UZH faculties, the University Hospital Zurich (USZ) and the University Children’s Hospital Zurich (KISPI). We engage in multi-disciplinary collaboration and training on all aspects associated with basic research into rare diseases and the translation of cutting-edge therapies into clinical practice.
ITINERARE builds on the work initiated by the Clinical Research Priority Program (CRPP) radiz (2012-2018), the long-standing collaborations with ethics and law, the ongoing CRPP ImmuGene (2019-2021), and the AcceleRare NCCR initiative (shortlisted for the 5th round of Swiss National Centers of Competence in Research by the SNSF). Translational studies involve the Swiss Rare Disease Registry (SRDR) that was initiated by radiz and is supported by UZH, as well as international networks in rare diseases. Together with the Therapy Development Accellerator (TDA) and the Clinical Trial Center of UZH, we will ensure the rapid (inter)national valorization of new therapies and research outcomes.